Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

'Atlastin,' Little-Known Protein, Builds Critical Structures; Does Job In Fundamentally New Way
Italian and U.S. biologists this week report that a little-understood protein previously implicated in a rare genetic disorder plays an unexpected and critical role in building and maintaining healthy cells. Even more surprising, their report in the journal Nature shows that the protein, called "atlastin," does its work by fusing intracellular membranes in a previously undocumented way.
generic viagra online
Discovery Of Gene Mutation Responsible For Hereditary Neuroendocrine Tumor
University of Utah researchers and their colleagues have identified the gene that is mutated in a hereditary form of a rare neuroendocrine tumor called paraganglioma (PGL). The gene, called hSDH5, is required for activation of an enzyme complex that plays a critical role in the chemical reactions that take place within cells to convert biochemical energy into usable energy. This study is published in the journal Science
News of the day
Baucus: Obama Open To Taxing Health Benefits To Pay For Health Reform
On the same day President Obama expressed the urgent need for health care reform, he also met with two dozen Senate Democrats and suggested that he is open to considering taxing employer-provided health benefits to pay for health care reform, The Washington Post reports.
Cardiovascular

Antibody Linked To Chemotherapy Drug Inhibits Ovarian Cancer In Lab

A novel anticancer agent, consisting of a monoclonal antibody linked to a chemotherapy drug, showed substantial antitumor activity in ovarian cancer cell lines and in mice, according to a study published online July 29 in the Journal of the National Cancer Institute. The agent, known as an immunoconjugate, targets a protein, EphA2, which is overexpressed in many human cancers but is absent or expressed at low levels in normal tissues. Anil K. Sood, M.D., of The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues tested the immunoconjugate in ovarian cancer cell lines, where it bound to cells with high levels of EphA2 but not to those without the protein. In mice, the EphA2 immunoconjugate inhibited tumor growth by 85% compared with that in mice treated with a control immunoconjugate, a highly statistically significant difference. In cell lines, its antitumor effects were also statistically significantly related to decreased proliferation and increased apoptosis of tumor cells. Chemotherapy drugs typically affect both tumor and normal tissues, which can result in side effects. The immunoconjugate tested by the in this study allows for highly selective delivery of chemotherapy. "In summary," the authors write, "the findings herein provide a novel EphA2-targeted immunoconjugate with potent antitumor activity in ovarian carcinoma. Further preclinical and clinical developmentò€¦appears to be warranted." Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009